Ajooni Biotech Limited
Ajooni Biotech Limited (AJOONI) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
ajoonibiotech.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|
| Sales | 29 Cr | 31 Cr | 32 Cr | 59 Cr |
| Operating expenses (approx.) | 28 Cr | 31 Cr | 30 Cr | 56 Cr |
| EBITDA | 1 Cr | 0.71 Cr | 2 Cr | 3 Cr |
| OPM % | 3.5% | 2.3% | 4.7% | 5.2% |
| Other income | 1 Cr | 0.65 Cr | 0.15 Cr | 0.32 Cr |
| Interest | 0.06 Cr | 0.08 Cr | 0.17 Cr | 0.18 Cr |
| Depreciation | 0.38 Cr | 0.25 Cr | 0.25 Cr | 0.81 Cr |
| Profit before tax | 2 Cr | 1 Cr | 1 Cr | 2 Cr |
| Tax % | 19.2% | 23.9% | 24.4% | 30.1% |
| Net profit | 2 Cr | 0.78 Cr | 0.93 Cr | 2 Cr |
| EPS (₹) | ₹0.09 | ₹0.02 | ₹0.08 | ₹0.10 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 115 Cr | Sign in for TTM |
| Operating expenses (approx.) | 111 Cr | Sign in for TTM |
| EBITDA | 4 Cr | Sign in for TTM |
| OPM % | 3.2% | Sign in for TTM |
| Other income | 2 Cr | Sign in for TTM |
| Interest | 0.33 Cr | Sign in for TTM |
| Depreciation | 1 Cr | Sign in for TTM |
| Profit before tax | 4 Cr | Sign in for TTM |
| Tax % | 22.1% | Sign in for TTM |
| Net profit | 3 Cr | Sign in for TTM |
| EPS (₹) | ₹0.20 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 34 Cr |
| Reserves | 54 Cr |
| Borrowings | 2 Cr |
| Other liabilities | 5 Cr |
| Total liabilities | 95 Cr |
| Fixed assets (net) | 11 Cr |
| CWIP | 0.29 Cr |
| Investments | 3 Cr |
| Loans & advances | 13 Cr |
| Inventories | 24 Cr |
| Trade receivables | 16 Cr |
| Cash & bank | 7 Cr |
| Other assets | 20 Cr |
| Total assets | 95 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | -18 Cr |
| Cash from investing | -17 Cr |
| Cash from financing | 25 Cr |
| Net cash flow | -10 Cr |
| Free cash flow (OCF − Capex) | -20 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 5.2% |
| ROE % | 3.8% |
| Debtor days | 51 |
| Inventory days | 90 |
| Days payable | 13 |
| Cash conversion cycle | 128 |
| Debt / equity | 0.02 |
| Current ratio | 12.86 |
| Net debt / EBITDA | -1.33 |